Scientific Research as a Foundation for Advancing Healthcare and Innovation: An Interview with Astghik Voskanyan
At the Yeolyan Hematology and Oncology Center, scientific research is a key area of activity aimed at improving the quality of medical care, exploring contemporary therapeutic approaches, and fostering international scientific collaboration.
What research projects are currently underway at the Center? Which innovative therapeutic approaches are being investigated? How does international collaboration strengthen the research capacity of Armenian specialists?
We discussed these questions with Astghik Voskanyan, Deputy Director for the Scientific Division of Yeolyan Hematology and Oncology Center.
– Scientific research is one of the core areas of activity at Yeolyan Hematology and Oncology Center. What research projects are currently being conducted at the Center?
Astghik Voskanyan: Scientific research at Yeolyan Center focuses on hematological and oncological diseases, improving diagnostic and treatment outcomes, and translating advances in modern medical science into clinical practice.
The Center is currently conducting a range of research projects encompassing basic and applied research, as well as clinical studies.
One key research area is investigating the relationship between immune system parameters in cancer patients and their responses to immunotherapy. This project is being implemented with grant support from the Ministry of Education, Science, Culture and Sport of the Republic of Armenia.
Another important area is the establishment and maintenance of national registries for benign and malignant diseases of the hematopoietic system. The Center maintains national registries for chronic lymphocytic leukemia, acute leukemias, Philadelphia chromosome-negative myeloproliferative neoplasms, non-Hodgkin lymphomas, and thalassemia. The myelodysplastic syndromes registry is maintained in collaboration with French partners. The Center is also involved in the international INHERENT research network on hemoglobinopathies.
Clinical research also covers maintenance therapy for acute myeloid leukemia, prevention of thrombotic complications in patients with multiple myeloma, novel medications for hemophilia, congenital antithrombin deficiency, and other hematologic disorders. Research is also being conducted to investigate a possible association between Helicobacter pylori infection and non-Hodgkin lymphomas in Armenia.
These diverse projects help strengthen local research capacity and establish systematic disease databases, which are essential for improving diagnostic and therapeutic approaches.
-Research at the Center also involves the investigation of new medications and therapeutic approaches. Which areas hold the greatest promise for potentially transforming the treatment of hematologic diseases in the future?
Astghik Voskanyan: An important area of the Center’s clinical research is the evaluation of the efficacy and safety of new medications. In particular, we are investigating novel treatments for patients with hemophilia A and B, the use of oral azacitidine as maintenance therapy for acute myeloid leukemia, and different approaches to preventing thrombotic complications in patients with multiple myeloma.
These studies are important for evaluating potential new treatment options and generating scientific evidence on their efficacy and safety. Their findings may contribute to the further refinement of therapeutic approaches, taking into account the specific characteristics of each disease.
At the same time, it is important to emphasize that the potential use of investigational medications or methods is determined on the basis of clinical trial results and applicable regulatory requirements.
– To what extent does the Center collaborate with leading international research and medical institutions? What opportunities does this create for Armenian specialists?
Astghik Voskanyan: International collaboration is an integral component of the Center’s research activities. Our specialists participate in international research networks and collaborative projects, attend scientific conferences, present their findings, and publish scientific articles.
One example of this collaboration is the maintenance of the myelodysplastic syndromes registry in partnership with colleagues in France. The Center also participates in the international INHERENT research network on hemoglobinopathies and in the European LeukemiaNet’s ERNEST 3 observational study involving patients with myelofibrosis.
These collaborations enable Armenian specialists to participate in multicenter studies, compare local data with international evidence, gain experience in contemporary research methodologies, and strengthen their professional and scientific capabilities.
International partnerships are also important because they allow data collected in Armenia to be incorporated into a broader scientific context. This not only strengthens research capacity but also supports the ongoing advancement of approaches to the investigation and treatment of hematologic diseases.
Our goal is to continuously develop the research environment, encourage greater participation in scientific studies, and strengthen international collaboration, ensuring that research contributes directly to improving the quality of medical care.
– What role do national registries play in advancing research and clinical practice?
Astghik Voskanyan: National registries are particularly important for studying diseases that require long-term follow-up, comparative analyses, and assessment of real-world treatment outcomes.
Clinical trials provide high-quality scientific evidence, while real-world clinical data complement these findings by demonstrating how therapeutic approaches perform in different settings and across diverse patient populations.
Databases established in Armenia enable us to study disease progression in our population, evaluate treatment outcomes, and identify questions that may form the basis of future research. Combining such data through international collaboration can increase their scientific value and contribute to broader, more comprehensive conclusions.
However, the value of registries depends not only on the volume of data but also on their quality, completeness, consistent collection, and methodological rigor in analysis. Our goal is to continue developing this area and establish registries as a reliable foundation for research planning and evidence generation.
– What is your vision for the future development of scientific research at Yeolyan Center?
Astghik Voskanyan: Our vision is to create a research environment in which clinical experience, scientific inquiry, and international collaboration complement and reinforce one another.
Achieving this requires the continuous development of national registries, broader participation in clinical research, greater involvement of young specialists and researchers in scientific activities, and stronger collaboration with international partners.
It is also important to view research as a long-term investment. Research findings do not always translate immediately into new therapeutic approaches; however, every high-quality study can help address gaps in knowledge, raise new questions, and lay the groundwork for further progress.
Ultimately, there is one overarching goal: scientific research must serve patients. We strive to ensure that the research capacity developed at Yeolyan Center contributes not only to the growth of our institution but also to the advancement of hematology and oncology in Armenia, supporting the continuous development of evidence-based, modern, and high-quality medical care.